证券代码：688581 证券简称：安杰思 公告编号：2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开了第二届董事会第十九次会议以及第二届监事会第十五次会议，审议通过 了《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相 关议案，并于 2025 年 4 月 23 日在上海证券交易所网站（www.sse.com.cn）上披 露了相关公告。 根据《上市公司信息披露管理办法》《上市公司股权激励管理办法》《上海证 券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权 激励信息披露》等法律、法规及规范性文件的要求，公司对 2025 年限制性股票 激励计划（以下简称"本激励计划"）采取了充分必要的保密措施，同时对本激 励计划内幕信息知情人进行了登记管理。并对本激励计划内幕信息知情人在本激 励计划公告前六个月买卖公司股票情况进行查询，实际查询期间为 2024 年 10 月 21 日至 2 ...

6月10日，安杰思今日收盘64.97元，上涨1.83%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到17.72倍，创12天以来新低，总市值52.61亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.00倍，行业中值37.03倍，安杰思排名 第41位。 截至2025年一季报，共有11家机构持仓安杰思，其中基金6家、其他5家，合计持股数1773.25万股，持 股市值12.60亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。报告期内，公司取得重要政府荣誉7项，获 得"浙江省级企业技术中心"、"浙江省生物医药高成长型企业"、"浙江省首批两新重大科技成果"、"杭 州市绿色工厂"、"杭州市优质产品（止血夹）2023年杭州市总部企业"等荣誉。 最新一期业绩显示，2025年一季报，公司实现营业收入1.29亿元，同比15.27%；净利润5624.83万元， 同比6.57%，销售毛利率70.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)41安杰思17.7217.93 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjisi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of May 29, Anjisi's closing stock price was 64.92 yuan, reflecting a 1.41% increase, with a rolling price-to-earnings (PE) ratio of 17.71 times and a total market capitalization of 5.257 billion yuan [1] - The average PE ratio for the medical device industry is 49.64 times, with a median of 36.36 times, positioning Anjisi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjisi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjisi's main business involves the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report, Anjisi reported a revenue of 129 million yuan, representing a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, with a year-on-year growth of 6.57%, and a gross profit margin of 70.68% [1]

Meeting Details - The first meeting of the third Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The meeting was convened following the election of the non-employee representative members at the annual shareholders' meeting [1] Resolutions Passed - The Supervisory Board approved the election of Mr. Shi Baoming as the chairman of the third Supervisory Board, with his term starting from the date of this meeting until the end of the current board's term [1][2] - The voting results were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2]

Core Viewpoint - The shareholders' meeting of Hangzhou Anjisi Medical Technology Co., Ltd. was held on May 16, 2025, with all proposed resolutions approved by the shareholders [1][6]. Meeting Details - The meeting took place at Room 302, 3rd Floor, No. 389 Xingzhong Road, Linping District, Hangzhou [1]. - A total of 48 ordinary shareholders attended the meeting, holding 57,830,094 voting rights, which accounted for 71.77% of the company's total voting rights [1]. Voting Results - All non-cumulative voting proposals were approved, with the following voting results: - Proposal 1: 57,694,589 votes in favor (99.77%), 121,105 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 2: 57,691,389 votes in favor (99.76%), 124,305 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 3: 57,692,589 votes in favor (99.76%), 137,505 votes against (0.24%), and no abstentions [3]. Election of Directors - The election of directors was conducted with the following results: - Zhang Cheng was elected with 55,363,070 votes (95.73%) [3]. - Zhang Qianyi was elected with 55,363,071 votes (95.73%) [3]. - Shen Menghui was elected with 55,392,711 votes (95.79%) [4]. - Feng Yang was elected with 55,392,710 votes (95.79%) [4]. Legal Compliance - The meeting and voting procedures complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions passed [6].

Core Viewpoint - The legal opinion provided by Beijing Deheng (Hangzhou) Law Firm confirms the legality of the 2024 annual general meeting of Hangzhou Anjisi Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][3][12] Group 1: Meeting Procedures - The annual general meeting is scheduled for May 16, 2025, with proper notification published on the Shanghai Stock Exchange and other designated media [3][4] - The meeting will utilize a combination of on-site and online voting methods, with specific timeframes for both [4][5] - The meeting's procedures for convening and conducting are deemed compliant with the Company Law and other relevant regulations [4][5] Group 2: Attendance and Voting - The record date for shareholder attendance is set for May 12, 2025, with 48 shareholders and their proxies representing 57,830,094 shares, accounting for 71.7701% of the total voting shares [4][5] - The voting results indicate a high level of agreement among shareholders, with significant support from minority investors [6][7][8] Group 3: Voting Results - A total of 18 agenda items were voted on, with the majority receiving overwhelming support, including votes from minority shareholders [5][6][9] - Specific resolutions, such as the election of directors and supervisors, received substantial approval, reflecting strong shareholder confidence [10][11] Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, are in accordance with the Company Law and the company's articles of association, rendering the resolutions valid [12]

Core Viewpoint - The company has completed the election of its third board of directors and supervisory board, along with the appointment of senior management personnel, marking a significant governance transition [1][3]. Board of Directors Election - The third board of directors consists of two non-independent directors, two independent directors, and one employee representative director, with a term of three years starting from the approval date of the 2024 annual general meeting [1][2]. - Zhang Cheng was elected as the chairman of the board, and various specialized committees were formed, including the audit committee, nomination committee, compensation and assessment committee, and strategic committee [2]. Supervisory Board Election - The third supervisory board includes two non-employee representative supervisors and one employee representative supervisor, with a term of three years starting from the approval date of the 2024 annual general meeting [3][4]. - Shi Baoming was elected as the chairman of the supervisory board [4]. Senior Management Appointments - The company appointed a new general manager, deputy general managers, a financial director, and a board secretary, all of whom meet the qualifications required by relevant laws and regulations [4][5]. - The board secretary, Zhang Qinhua, holds the necessary qualifications to perform his duties effectively [4][5]. Securities Affairs Representative Appointment - Du Xinyu was appointed as the securities affairs representative, assisting the board secretary with daily securities matters [5][10]. Departure of Previous Board Members - Following the completion of the election, three previous board members, including Sheng Yueyuan and independent directors Wu Jianhai and Xia Lianan, have completed their terms and are no longer serving on the board [6][7].

Core Viewpoint - The company has completed a capital increase for its subsidiary, Hang An Medical Technology, to implement an employee stock ownership plan, resulting in a decrease in the company's shareholding to 90.9091% [1][2]. Group 1: Transaction Overview - Hang An Medical has introduced an employee stock ownership platform, Hangzhou Dingliang Enterprise Management Partnership, through a capital increase of 5 million yuan, with the company waiving its preferential subscription rights [1]. - The capital increase has been completed, and the company's shareholding in Hang An Medical has decreased to 90.9091%, changing its status from a wholly-owned subsidiary to a controlling subsidiary [1][2]. Group 2: Business Registration Completion - Hang An Medical has completed the business registration with the Hangzhou Linping District Market Supervision Administration and has received its business license [2]. - The registered capital of Hang An Medical is now 55 million yuan, and it operates in various medical device sectors, including the production and sale of Class II and Class III medical devices [2]. Group 3: Impact on the Listed Company - The transaction will not change the scope of the company's consolidated financial statements and will not adversely affect the company's operating results or financial condition [4].

关于全资子公司通过增资实施股权激励及公司放弃优先认 购权暨关联交易事项进展暨完成工商变更登记的公告 证券代码：688581 证券简称：安杰思 公告编号：2025-033 杭州安杰思医学科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提醒： 杭州安杰思医学科技股份有限公司（以下简称"公司"）子公司杭安医学 科技（杭州）有限公司（以下简称"杭安医学"）通过增资形式引入员工持 股平台杭州鼎亮企业管理合伙企业（有限合伙）（以下简称"杭州鼎亮"）， 公司放弃本次增资的优先认购权的事项已经公司第二届董事会第十九次会 议、第二届监事会第十五次会议审议通过。 杭安医学已于近日完成与本次增资相关的工商变更登记，公司对杭安医 学的持股比例下降至 90.9091%。杭安医学由公司全资子公司变更为公司的 控股子公司，公司合并报表范围未发生变化。 一、交易概述 为进一步落实公司的发展战略，优化子公司杭安医学的资本结构，同时建立 健全杭安医学的长效激励机制，提升杭安医学的运营及管理效率、可持续发展能 力及核心竞争力，吸引和留 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 5 月 16 日，杭州安杰思医学科技股份有限公司（以下简称"公司"） 召开 2024 年年度股东大会，选举产生了第三届董事会、监事会非职工代表成员， 与公司于 2025 年 4 月 21 日召开的职工代表大会选举产生的职工代表董事、职工 代表监事，共同组成公司第三届董事会、第三届监事会。同日，公司召开第三届 董事会第一次会议及第三届监事会第一次会议，分别选举产生了董事长、专门委 员会委员及监事会主席，并聘任第三届高级管理人员和证券事务代表。现将相关 情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 5 月 16 日，公司召开 2024 年年度股东大会，通过了《关于公司董 事会换届选举暨选举第三届董事会非独立董事的议案》《关于公司董事会换届选 举暨选举第三届董事会独立董事的议案》，选举张承先生、张千一女士为公司第 三届董事会非独立董事，选举沈梦晖先生、冯洋先生为公司第三届董事会独立董 事；2025 年 4 月 21 日，公司召开了第三届第二 ...